Atara Biotherapeutics (ATRA) News Today $7.11 -0.41 (-5.45%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.42 +0.31 (+4.36%) As of 02/21/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsFebruary 14, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAFebruary 11, 2025 | prnewswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAFebruary 4, 2025 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsFebruary 3, 2025 | globenewswire.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of "Moderate Buy" by AnalystsAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hoFebruary 1, 2025 | marketbeat.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsJanuary 30, 2025 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAJanuary 28, 2025 | prnewswire.comAtara stock holds Neutral rating after workforce cutJanuary 28, 2025 | msn.comATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJanuary 28, 2025 | prnewswire.comAtara reduction in workforce to impact 50% of current employeesJanuary 27, 2025 | msn.comAtara to cut 50% of workforce amid FDA woesJanuary 27, 2025 | msn.comATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJanuary 27, 2025 | businesswire.comAtara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL IssuesJanuary 23, 2025 | markets.businessinsider.comAtara Biotherapeutics price target lowered to $5 from $10 at StifelJanuary 22, 2025 | markets.businessinsider.comStifel cuts Atara Biotherapeutics target to $5, holds ratingJanuary 21, 2025 | msn.comAtara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold RatingJanuary 21, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAJanuary 21, 2025 | prnewswire.comUS FDA puts clinical hold on Atara's trials for cancer cell therapiesJanuary 21, 2025 | reuters.comAtara extends losses after FDA clinical holdJanuary 21, 2025 | msn.comAtara Biotherapeutics price target lowered to $17 from $21 at CanaccordJanuary 18, 2025 | markets.businessinsider.comBuy Rating for Atara Biotherapeutics Driven by Manufacturing Resolution and Strategic InitiativesJanuary 18, 2025 | markets.businessinsider.comAtara Bio reiterated at Buy by Canaccord on expected Ebvallo manufactureJanuary 17, 2025 | msn.comAtara Shares Sink After FDA Stalls Cancer TreatmentJanuary 16, 2025 | marketwatch.comAtara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO ApplicationJanuary 16, 2025 | sg.finance.yahoo.comAtara announces Ebvallo CRL did not find clinical efficacy deficienciesJanuary 16, 2025 | markets.businessinsider.comAtara Biotherapeutics trading halted, news pendingJanuary 16, 2025 | markets.businessinsider.comAtara stock plummets on FDA setback for EBV drugJanuary 16, 2025 | in.investing.comFDA Rejects Atara's Request to Bring Blood Cancer Treatment to MarketJanuary 16, 2025 | marketwatch.comAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)January 16, 2025 | stockhouse.comUS FDA declines to approve Atara Biotherapeutics' cancer therapyJanuary 16, 2025 | reuters.comAtara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last weekJanuary 8, 2025 | finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by BrokeragesAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assignedJanuary 7, 2025 | marketbeat.comBiotech Stocks Facing FDA Decision In January 2025January 1, 2025 | markets.businessinsider.comAtara Biotherapeutics, Inc. Common Stock (ATRA) Insider ActivityDecember 25, 2024 | nasdaq.comAtara Biotherapeutics (NASDAQ:ATRA) Raised to Strong-Buy at RODMAN&RENSHAWRODMAN&RENSHAW upgraded shares of Atara Biotherapeutics to a "strong-buy" rating in a report on Friday.December 21, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Atara Biotherapeutics (ATRA) with Buy RecommendationDecember 20, 2024 | msn.comAtara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Analysts at Rodman & RenshawRodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday. They set a "buy" rating and a $25.00 price objective for the company.December 20, 2024 | marketbeat.comRajani DinavahiDecember 15, 2024 | latimes.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by AnalystsShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, oneDecember 13, 2024 | marketbeat.comCentiva Capital LP Sells 96,847 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)Centiva Capital LP lowered its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 69.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,403 shares of the biotechnologDecember 10, 2024 | marketbeat.comAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceNovember 27, 2024 | businesswire.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $11,200.00 in StockNovember 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of "Hold" by BrokeragesShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been given a consensus rating of "Hold" by the four analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommNovember 18, 2024 | marketbeat.comEcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics IncNovember 15, 2024 | gurufocus.comAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceNovember 13, 2024 | businesswire.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group boosted their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comInsights into Atara Biotherapeutics's Upcoming EarningsNovember 11, 2024 | benzinga.comAtara Biotherapeutics (ATRA) to Release Earnings on TuesdayAtara Biotherapeutics (NASDAQ:ATRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Media Mentions By Week ATRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼0.100.60▲Average Medical News Sentiment ATRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼02▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRQR News INBX News CYBN News IVVD News NBTX News DRUG News PLRX News GNLX News SCPH News LYEL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts